Cyclophosphamide and ATG — Competitive Intelligence Brief

Cyclophosphamide and ATG (Cyclophosphamide and ATG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy. Area: Immunology.

phase 3 Immunosuppressive combination therapy Immunology Small molecule

Target snapshot

Cyclophosphamide and ATG (Cyclophosphamide and ATG) — Haukeland University Hospital. Cyclophosphamide and ATG work together to suppress the immune system by eliminating lymphocytes, allowing immune reconstitution and halting autoimmune disease progression.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyclophosphamide and ATG TARGET	Cyclophosphamide and ATG	Haukeland University Hospital	phase 3	Immunosuppressive combination therapy
Basiliximab, Tacrolimus, MMF	Basiliximab, Tacrolimus, MMF	University Hospital Freiburg	marketed	Immunosuppressive combination therapy	IL-2 receptor (basiliximab); calcineurin (tacrolimus); IMPDH (MMF)
Mycophenolate+Tacrolimus+Prednisone	Mycophenolate+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	T-cell proliferation and activation (multiple targets: IMPDH, calcineurin, glucocorticoid receptor)
CsA+Rapamune+CS	CsA+Rapamune+CS	Pfizer	marketed	Immunosuppressive combination therapy	Calcineurin, mTOR, glucocorticoid receptor
Sirolimus+MMF or MPS or AZA+Steroid	Sirolimus+MMF or MPS or AZA+Steroid	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Immunosuppressive combination therapy	mTOR (sirolimus); IMPDH (MMF/MPS); purine synthesis (AZA); glucocorticoid receptor (steroid)
Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Cyclophosphamide, Azathioprine,prednisone,methylprednisolone	Assistance Publique - Hôpitaux de Paris	marketed	Immunosuppressive combination therapy
Zenapax®, CellCept® and prednisolone	Zenapax®, CellCept® and prednisolone	University of Oslo School of Pharmacy	marketed	Immunosuppressive combination therapy	IL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy class)

1. University Hospital, Brest · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Fundação Pró Rim · 2 drugs in this class
4. Haukeland University Hospital · 1 drug in this class
5. Imperial College Healthcare NHS Trust · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Novartis · 1 drug in this class
8. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. Swiss Cancer Institute · 1 drug in this class
10. University Hospital Freiburg · 1 drug in this class